BAROSTIM THERAPY™ In Heart Failure with Reduced Ejection Fraction: A Post-Market Registry with the BAROSTIM NEO™ System
Objective
The purpose of this registry is to provide additional evidence of the safety and benefit of BAROSTIM THERAPY in the commercial setting in patients with heart failure with reduced ejection fraction (HFrEF) that were recently implanted with the BAROSTIM NEO System.
Eligibility
Patients can be included in the registry if they were implanted in the past 30 days with a de novo BAROSTIM NEO System for the treatment of heart failure. Patients must sign an IRB-approved informed consent form for the registry to participate.
NCT ID
NCT04502316
